Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Diplomat Pharmacy, Inc.
Report date February 10, 2020 · Filed February 10, 2020
Section 16 reporting ended · disclosed 2020-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-02-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-10 · Other · Disposed 19,453 · Balance 20,674 F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. Row 2 · 2020-02-10 · Disposition to issuer · Disposed 20,674 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest.
F2: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer.
InfuSystem Holdings, Inc
Report date October 15, 2018 · Filed October 17, 2018
Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,965 |
Ending reported balance
After 2018-10-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-10-15 · Exercise / conversion · Acquired 25,000 · Balance 25,000 Row 2 · 2018-10-15 · Tax withholding · Disposed 20,538 · Balance 4,462 F1: Reflects the number of shares surrendered in connection with the cashless exercise and tax withholding obligations for the exercised option. Row 3 · 2018-10-15 · Exercise / conversion · Acquired 20,833 · Balance 25,295 Row 4 · 2018-10-15 · Tax withholding · Disposed 15,330 · Balance 9,965 F1: Reflects the number of shares surrendered in connection with the cashless exercise and tax withholding obligations for the exercised option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2018-10-19 | Direct | 0 |
Reported balance
After 2018-10-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-10-15 · Exercise / conversion · Disposed 25,000 · Balance 0 F2: The option, representing the right to purchase a total of 25,000 shares, became exercisable in twelve equal monthly installments following the January 18, 2017 date of grant. F3: The reporting person ceased to be a Director of the Company on July 19, 2018. The option expires three months after the date Optionee ceased to be a Director of the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2018-10-19 | Direct | 0 |
Reported balance
After 2018-10-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-10-15 · Exercise / conversion · Disposed 20,833 · Balance 0 F4: The option, representing the right to purchase a total of 20,833 shares, became exercisable in ten equal monthly installments following the September 17, 2017 date of grant. All vesting ceased upon termination of the reporting person's service as a Director of the Company on July 19, 2018. F3: The reporting person ceased to be a Director of the Company on July 19, 2018. The option expires three months after the date Optionee ceased to be a Director of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of shares surrendered in connection with the cashless exercise and tax withholding obligations for the exercised option.
F2: The option, representing the right to purchase a total of 25,000 shares, became exercisable in twelve equal monthly installments following the January 18, 2017 date of grant.
F3: The reporting person ceased to be a Director of the Company on July 19, 2018. The option expires three months after the date Optionee ceased to be a Director of the Company.
F4: The option, representing the right to purchase a total of 20,833 shares, became exercisable in ten equal monthly installments following the September 17, 2017 date of grant. All vesting ceased upon termination of the reporting person's service as a Director of the Company on July 19, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 10, 2020 16:15 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 20,674 | $4.00 | $82,696.00 |
DisclosureSEC source: 0001104659-20-013501 · a4.xml · nonDerivative · entry 2 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:15 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | OtherCommon Stock | 19,453 | $4.00 | $77,812.00 |
DisclosureSEC source: 0001104659-20-013501 · a4.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,674 F1 · kind: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 16:31 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | SaleCommon Stock | 860 | $4.82 | $4,148.47 |
DisclosureSEC source: 0001596771-19-000118 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,127 F1 · kind: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F1 · shares: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F2 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $4.81 to $4.85. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:15 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | SaleCommon Stock | 1,274 | $4.85 | $6,184.76 |
DisclosureSEC source: 0001596771-19-000055 · primary_doc.xml · nonDerivative · entry 2 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,987 F2 · kind: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F2 · shares: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F3 · price: The price represents the weighted average price of the multiple transactions reported on this line. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:15 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 20,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-19-000055 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,261 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · derivative · entry 6 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,833 shares Expires 2018-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 20,833 shares, became exercisable in ten equal monthly installments following the September 17, 2017 date of grant. All vesting ceased upon termination of the reporting person's service as a Director of the Company on July 19, 2018. F3 · derivative.expiration_date: The reporting person ceased to be a Director of the Company on July 19, 2018. The option expires three months after the date Optionee ceased to be a Director of the Company. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · derivative · entry 5 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2018-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares, became exercisable in twelve equal monthly installments following the January 18, 2017 date of grant. F3 · derivative.expiration_date: The reporting person ceased to be a Director of the Company on July 19, 2018. The option expires three months after the date Optionee ceased to be a Director of the Company. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Tax withholdingCommon Stock | 15,330 | $3.24 | $49,669.20 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · nonDerivative · entry 4 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,965 F1 · shares: Reflects the number of shares surrendered in connection with the cashless exercise and tax withholding obligations for the exercised option. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Exercise / conversionCommon Stock | 20,833 | $1.98 | $41,249.34 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · nonDerivative · entry 3 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Tax withholdingCommon Stock | 20,538 | $3.24 | $66,543.12 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · nonDerivative · entry 2 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462 F1 · shares: Reflects the number of shares surrendered in connection with the cashless exercise and tax withholding obligations for the exercised option. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:52 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | Exercise / conversionCommon Stock | 25,000 | $2.39 | $59,750.00 |
DisclosureSEC source: 0001437749-18-018380 · rdgdoc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:11 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 2,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000093 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,587 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's revised non-employee director compensation program, effective October 1, 2018. Read SEC document |
| June 18, 2018 Filed Jun 26, 2018 16:31 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | SaleCommon Stock | 24,719 | $3.15 | $77,864.85 |
DisclosureSEC source: 0001014108-18-000163 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These shares were originally part of an order, the balance of which traded and were reported on Form 4 on June 14, 2018. The order was believed cancelled until the holder received another trade confirmation reporting the completion of the order on June 18, 2018. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 10:51 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | SaleCommon Stock | 105,715 | $3.10 | $327,716.50 |
DisclosureSEC source: 0001014108-18-000162 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,719 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:28 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 3,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000068 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,312 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 19:32 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001014108-17-000155 · primary_doc.xml · derivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-09-07 F1 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares of InfuSystem Holdings, Inc. common stock, vests in twelve monthly installments beginning October 7, 2017. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 16:13 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-17-000044 · primary_doc.xml · nonDerivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,658 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| January 18, 2017 Filed Jan 27, 2017 16:10 UTC | InfuSystem Holdings, Inc INFU · Entity 6163 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001014108-17-000012 · primary_doc.xml · derivative · entry 1 DREYER DAVID C · CIK 0001203607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares of InfuSystem Holdings, Inc. common stock, vests in twelve monthly installments beginning February 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.